Publications by authors named "Mark Khan"

Claim this Profile
I
Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study.
Sue Ann Costa Clemens, Brett Jepson, Qasim E Bhorat, Abdullahi Ahmad, Tauseefullah Akhund, Mark Khan

Lancet Microbe· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland.
Maheshi N Ramasamy, Elizabeth J Kelly, Seth Seegobin, Paul I Dargan, Ruth Payne, Mark Khan

Lancet Microbe· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Review of small intestine submucosa extracellular matrix technology in multiple difficult-to-treat wound types.
Jennifer Chang, Nicholas DeLillo, Mark Khan, Mario R Nacinovich

Wounds· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis